DK0960105T3 - Benzofurazanforbindelser, der foröger AMPA-receptoraktivitet - Google Patents

Benzofurazanforbindelser, der foröger AMPA-receptoraktivitet

Info

Publication number
DK0960105T3
DK0960105T3 DK98906358T DK98906358T DK0960105T3 DK 0960105 T3 DK0960105 T3 DK 0960105T3 DK 98906358 T DK98906358 T DK 98906358T DK 98906358 T DK98906358 T DK 98906358T DK 0960105 T3 DK0960105 T3 DK 0960105T3
Authority
DK
Denmark
Prior art keywords
compounds
ampa receptor
receptor activity
receptors
ampa
Prior art date
Application number
DK98906358T
Other languages
Danish (da)
English (en)
Inventor
Gary A Rogers
Christopher M Marrs
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of DK0960105T3 publication Critical patent/DK0960105T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Luminescent Compositions (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Furan Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK98906358T 1997-02-13 1998-02-13 Benzofurazanforbindelser, der foröger AMPA-receptoraktivitet DK0960105T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/800,108 US6110935A (en) 1997-02-13 1997-02-13 Benzofurazan compounds for enhancing glutamatergic synaptic responses

Publications (1)

Publication Number Publication Date
DK0960105T3 true DK0960105T3 (da) 2004-08-30

Family

ID=25177504

Family Applications (2)

Application Number Title Priority Date Filing Date
DK04075259T DK1428534T3 (da) 1997-02-13 1998-02-13 Benzofurazanderivater til forögelse af glutaminerge synaptiske responser
DK98906358T DK0960105T3 (da) 1997-02-13 1998-02-13 Benzofurazanforbindelser, der foröger AMPA-receptoraktivitet

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK04075259T DK1428534T3 (da) 1997-02-13 1998-02-13 Benzofurazanderivater til forögelse af glutaminerge synaptiske responser

Country Status (24)

Country Link
US (3) US6110935A (de)
EP (2) EP0960105B1 (de)
JP (1) JP4446023B2 (de)
KR (1) KR100544295B1 (de)
CN (1) CN1085206C (de)
AT (2) ATE266649T1 (de)
AU (1) AU737802C (de)
BR (1) BR9807333B1 (de)
CA (1) CA2279319C (de)
CZ (1) CZ299765B6 (de)
DE (2) DE69823803T2 (de)
DK (2) DK1428534T3 (de)
ES (2) ES2221152T3 (de)
GB (1) GB2325225B (de)
HU (1) HUP0002303A3 (de)
ID (1) ID22342A (de)
IL (1) IL131200A (de)
NO (1) NO318935B1 (de)
NZ (1) NZ336980A (de)
PL (1) PL199135B1 (de)
PT (2) PT960105E (de)
RU (1) RU2189984C2 (de)
TR (1) TR199901941T2 (de)
WO (1) WO1998035950A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN188837B (de) 1998-05-22 2002-11-09 Torrent Pharmaceuticals Ltd
AU2002366756A1 (en) * 2001-12-20 2003-07-09 Alangudi Sankaranarayanan Use of benzofuroxan derivatives as antiplatelet agents
WO2004062616A2 (en) * 2003-01-13 2004-07-29 Cortex Pharmaceuticals, Inc. Method of treating cognitive decline due to sleep deprivation and stress
DK1636215T3 (da) * 2003-05-23 2008-06-02 Basilea Pharmaceutica Ag Furazanobenzimidazoler
US20050228019A1 (en) * 2004-01-26 2005-10-13 Cortex Pharmaceuticals, Inc. Enhancement of ampakine-Induced facilitation of synaptic responses by cholinesterase inhibitors
BRPI0716375A2 (pt) * 2006-08-31 2013-10-15 Univ Alberta Método para reduzir ou inibir depressão respiratória em um sujeito; método para induzir analgesia, anestesia ou sedação em um sujeito, reduzindo ou inibindo simultaneamente depressão respiratória no sujeito; e composição farmacêutica para induzir analgesia, anestesia ou sedação em um sujeito...
AU2007342364A1 (en) * 2007-01-03 2008-07-17 Cortex Pharmaceuticals, Inc. 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses
MY154877A (en) * 2007-01-03 2015-08-14 Servier Lab 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamateric synaptic responses
EA200901546A1 (ru) 2007-05-17 2010-04-30 Кортекс Фармасеутикалс, Инк. Дизамещенные амиды для усиления глутаматергических синаптических ответов
US8119632B2 (en) 2007-08-10 2012-02-21 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
BRPI0814149A2 (pt) 2007-08-10 2011-09-13 Cortex Pharma Inc composto, composição farmacêutica, métodos de tratamento e uso do composto
US8071914B2 (en) * 2007-12-26 2011-12-06 Noboru Oshima Heating apparatus
US20110218190A1 (en) * 2008-11-10 2011-09-08 The Regents Of The University Of California Therapeutic uses of ampa receptor modulators for treatment of motor dysfunction
BRPI1005316A2 (pt) * 2009-02-02 2019-09-24 Cortex Pharmaceuticals, Inc. composto, composição farmacêuttca, métodos para tratamento e uso de um composto
US20130058915A1 (en) 2010-03-02 2013-03-07 Children's Medica Center Corporation Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
US20110257186A1 (en) * 2010-04-15 2011-10-20 Staubli Ursula V Compositions and methods for treating visual disorders
US9700596B2 (en) 2011-03-04 2017-07-11 The Regents Of The University Of California Locally released growth factors to mediate motor recovery after stroke
CN102633731B (zh) * 2012-03-13 2014-04-30 四川大学华西医院 6-喹喔啉甲酸酰胺化合物、制备方法和应用
KR101421032B1 (ko) * 2012-12-28 2014-07-22 주식회사 레고켐 바이오사이언스 (2-메틸-1-(3-메틸벤질)-1Ｈ-벤조[d]이미다졸-5일)(피페리딘-5-일)메탄온의 제조방법
BR112015031249A2 (pt) 2013-06-13 2017-07-25 Veroscience Llc método de tratamento, método para tratar um distúrbio metabólico ou um elemento chave do mesmo, método para normalizar um ritmo diário de liberação de dopamina no sumn, método para estimular a liberação de dopamina de neurônios dopaminérgicos no sumn de um indivíduo e composição farmacêutica
US20190112300A1 (en) 2016-03-29 2019-04-18 Arnold Stan Lippa Compositions And Methods For Treating Attention Deficit Disorders
CN107286114B (zh) 2016-04-13 2020-08-18 中国人民解放军军事医学科学院毒物药物研究所 Ampa受体增效剂的脑靶向前药及其医药用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3981864A (en) * 1973-09-08 1976-09-21 Eisai Co., Ltd. 1,3-Benzodioxol derivatives
FR2499991A1 (fr) * 1981-02-19 1982-08-20 Sandoz Sa Nouveaux 2,1,3-benzothiadiazoles et 2,1,3-benzoxadiazoles, leur preparation et leur application comme medicaments
US4420485A (en) * 1982-09-29 1983-12-13 Hoechst-Roussel Pharmaceuticals Inc. 1'-[3-(1,2-Benzisoxazol-3-yl) proply]spiro[benzofuran-2(3H),3' or 4'-piperidines or 3'-pyrrolidines]
SU1657189A1 (ru) * 1988-05-23 1991-06-23 Научно-Исследовательский Институт Экспериментальной Медицины Амн Ссср Способ коррекции апато-абулических состо ний при шизофрении
SU1587050A1 (ru) * 1988-12-23 1990-08-23 Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского Производные (7-бромбензо-2,1,3-тиадиазол-4-сульфонил)амина в качестве промежуточных продуктов в синтезе 2-[(7-бромбензо-2,1,3-тиадиазол-4-сульфонил)амино]-5-бром-N-(4-хлорфенил)бензамида, обладающего антигельминтной активностью
US5112824A (en) * 1989-12-08 1992-05-12 Merck & Co., Inc. Benzofuran compounds as class III antiarrhythmic agents
IL96507A0 (en) * 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
US5032604A (en) * 1989-12-08 1991-07-16 Merck & Co., Inc. Class III antiarrhythmic agents
EP1156043B1 (de) * 1992-07-24 2003-11-12 The Regents Of The University Of California Arzneimittel die den durch AMPA Rezeptoren vermittelten synaptischen Response erhöhen
DE59504622D1 (de) * 1994-10-31 1999-02-04 Merck Patent Gmbh Benzylpiperidinderivate mit hoher Affinität zu Bindungsstellen von Aminosäure-Rezeptoren
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
US5985871A (en) 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response

Also Published As

Publication number Publication date
GB2325225B (en) 1999-03-03
NO318935B1 (no) 2005-05-30
CA2279319C (en) 2008-08-05
PL199135B1 (pl) 2008-08-29
GB2325225A8 (en) 1999-02-17
KR100544295B1 (ko) 2006-01-23
TR199901941T2 (xx) 1999-12-21
US20020055508A1 (en) 2002-05-09
GB9809221D0 (de) 1998-07-01
US6730677B2 (en) 2004-05-04
ES2264078T3 (es) 2006-12-16
CZ299765B6 (cs) 2008-11-19
AU737802B2 (en) 2001-08-30
US6110935A (en) 2000-08-29
IL131200A (en) 2005-06-19
WO1998035950A1 (en) 1998-08-20
AU6159998A (en) 1998-09-08
JP2001512459A (ja) 2001-08-21
PT960105E (pt) 2004-09-30
PT1428534E (pt) 2006-07-31
RU2189984C2 (ru) 2002-09-27
ATE326221T1 (de) 2006-06-15
AU737802C (en) 2005-05-12
GB2325225A (en) 1998-11-18
NO993768D0 (no) 1999-08-04
CZ279599A3 (cs) 2000-01-12
NO993768L (no) 1999-09-23
NZ336980A (en) 2000-08-25
BR9807333B1 (pt) 2011-10-18
DE69823803T2 (de) 2005-04-14
HUP0002303A3 (en) 2002-09-30
EP1428534A1 (de) 2004-06-16
CA2279319A1 (en) 1998-08-20
HUP0002303A2 (hu) 2001-04-28
EP1428534B1 (de) 2006-05-17
ES2221152T3 (es) 2004-12-16
ID22342A (id) 1999-09-30
DE69834590T2 (de) 2007-04-26
CN1085206C (zh) 2002-05-22
DE69834590D1 (de) 2006-06-22
DE69823803D1 (de) 2004-06-17
KR20000071082A (ko) 2000-11-25
ATE266649T1 (de) 2004-05-15
JP4446023B2 (ja) 2010-04-07
US6313115B1 (en) 2001-11-06
EP0960105A1 (de) 1999-12-01
DK1428534T3 (da) 2006-06-12
PL335058A1 (en) 2000-03-27
CN1247534A (zh) 2000-03-15
IL131200A0 (en) 2001-01-28
EP0960105B1 (de) 2004-05-12
BR9807333A (pt) 2000-04-18

Similar Documents

Publication Publication Date Title
GB2325225B (en) Benzofurazan compounds which enhance AMPA receptor activity
DK0891365T3 (da) Benzoxaziner til forstærkning af synaptiske responser
DE69811363D1 (de) Piperazin-derivate und ihre verwendung als entzündungshemmende mittel
BR9106665A (pt) Derivados de quinuclidina
DE69920497D1 (de) Liponsaürederivate und deren verwendung bei der behandlung von krankheiten
UY26249A1 (es) Moléculas pequenas útiles en el tratamiento de las enfermedades inflamatorias ley 17164 art. 127
PT839134E (pt) Benzoilpiperidinas/pirrolidinas para melhoramento da resposta sinaptica
DE60033530D1 (de) Humane antikörper gegen ctla-4 und deren verwendungen
BR0015416A (pt) Composições contendo derivados do ácido hidroxieicosa tetraenóico e métodos de uso no tratamento de distúrbios de olhos secos
DE69435303D1 (de) Er behandlung von krankheiten bei denen eine cytok
CY1105557T1 (el) Θεραπεια της σχιζοφρενειας με αμπακινες και νευροληπτικα φαρμακα
DK1054673T3 (da) Benzoxazinforbindelser til forstærkelse af synaptisk reaktion
EA200500934A1 (ru) Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
PT1067935E (pt) Acilbenzoxazinas para melhorar resposta (s) sinaptica (s)
BR0015402A (pt) Derivados de ácido 15-hidroxieicosatetraenóico de cadeia Èmega modificada e métodos de seu uso para o tratamento de olho seco
PT889044E (pt) Derivados do 5-(heteroaril)alquil-3-oxo-pirido-(1,2-a)benzimidazole-4-carboxamida (pbi) uteis no tratamento de perturbacoes do sistema nervoso central
ES2061739T3 (es) 5-(amino-sustituida)-8-(fenil o fenil-sustituidas)-3h,6h-1,4,5a,8a-tetraazaacenaftilen-3-onas, que son utiles como agentes para el tratamiento de trastornos del comportamiento cognitivo y neural asociado con el mismo en animales mamiferos.
TH28200B (th) การใช้ (สูตร) il -อะโกนิสท์สำหรับรักษาการกลั้นปัสสาวะไม่อยู่
CA2249654A1 (en) Benzoxazines for enhancing synaptic response